# OnCo record amphista-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/amphista-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "amphista-therapeutics" ;
  schema:name "Amphista Therapeutics"@en ;
  schema:description "Amphista Therapeutics, based near Cambridge in the UK, designs small molecules that make cancer cells destroy specific proteins using a less common disposal enzyme called DCAF16. Its first drug, for acute myeloid leukaemia, was cleared to start human trials in 2026."@en ;
  schema:url <https://onco.cc/companies/amphista-therapeutics/>, <https://amphista.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://amphista.com/>, <https://amphista.com/pipeline/>, <https://amphista.com/amphista-therapeutics-announces-fda-clearance-of-ind-application-for-amx-883-its-lead-targeted-glue-degrader-for-acute-myeloid-leukaemia/> ;
  schema:addressCountry "GB" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/mesothelioma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/epigenetics/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/synthetic-lethality-approaches/> .